Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-147 Phase 2/3 study in APOL1-mediated proteinuric kidney disease
2021-004762-35Phase 2Active
- Sponsor
- Vertex Pharmaceuticals
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in APOL1-mediated kidney disease (AMKD) comparing Inaxaplin with Placebo (2 arms). Primary endpoint: Percent change in UPCR from baseline at Week 48. Started May 2022; status: active.
02
Drugs
inaxaplin
03
Conditions
APOL1-mediated kidney disease (AMKD)
Beyond the preview
Go deeper on 2021-004762-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004762-35.